Literature DB >> 11381570

Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

J P Hing1, S G Woolfrey, D Greenslade, P M Wright.   

Abstract

The purpose of this study was to evaluate whether mixed effects modeling (MEM) performs better than either noncompartmental or compartmental naïve pooled data (NPD) analysis for the interpretation of single sample per subject pharmacokinetic (PK) data. Using PK parameters determined during a toxicokinetic study in rats, we simulated data sets that might emerge from similar experiments. Data sets were simulated with varying numbers of animals at each sampling time (4-48) and the number of samples taken (1-3) from each individual. Each data set was replicated 50 times and analyzed using several variations of MEM that differed in the assumptions made regarding intraindividual error, NPD, and a graphical noncompartmental method. These analyses attempted to retrieve the underlying parameter and covariate effect values. We compared these analysis methods with respect to how well the underlying values were retrieved. All analysis methods performed poorly with single sample per subject data but MEM gave less biased estimates under the simulated conditions used here. MEM performance increased when covariate effects were sought in the analysis compared with analyses seeking only PK parameters. Decreasing the number of animals used per sampling time from 48 to 16 did not influence the quality of parameter estimates but further reductions (< 16 animals per sampling time) resulted in a reduced proportion of acceptable estimates. Parameter estimate quality improved and worsened with MEM and NPD, respectively, when additional samples were obtained from each individual. Assumptions made regarding the magnitude of intraindividual error were unimportant with single sample per subject data but influenced parameter estimates if more samples were obtained from each individual. MEM is preferable to both NPD and noncompartmental approaches for the analysis of single sample per subject data but even with MEM estimates of clearance are often biased.

Entities:  

Mesh:

Year:  2001        PMID: 11381570     DOI: 10.1023/a:1011507100493

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  11 in total

1.  Experimental design and efficient parameter estimation in population pharmacokinetics.

Authors:  M K al-Banna; A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

2.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

3.  Analysis of animal pharmacokinetic data: performance of the one point per animal design.

Authors:  E I Ette; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

4.  Resampling methods in sparse sampling situations in preclinical pharmacokinetic studies.

Authors:  H Mager; G Göller
Journal:  J Pharm Sci       Date:  1998-03       Impact factor: 3.534

5.  Characterization of AUCs from sparsely sampled populations in toxicology studies.

Authors:  S M Pai; S H Fettner; G Hajian; M N Cayen; V K Batra
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

6.  Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.

Authors:  E I Ette; C A Howie; A W Kelman; B Whiting
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

7.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

8.  Estimation of population pharmacokinetic parameters using destructively obtained experimental data: a simulation study of the one-compartment open model.

Authors:  F T Lindstrom; D S Birkes
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

9.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more
  11 in total

1.  Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse.

Authors:  Ahmed A Othman; Amy H Newman; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2008-12       Impact factor: 3.534

3.  Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Authors:  Shuiying Hu; Hongmei Niu; Hiroto Inaba; Shelley Orwick; Charles Rose; John C Panetta; Shengping Yang; Stanley Pounds; Yiping Fan; Christopher Calabrese; Jerold E Rehg; Dario Campana; Jeffrey E Rubnitz; Sharyn D Baker
Journal:  J Natl Cancer Inst       Date:  2011-04-12       Impact factor: 13.506

4.  Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3.

Authors:  Olivier Nicolas; Delphine Margout; Nicolas Taudon; Sharon Wein; Michèle Calas; Henri J Vial; Françoise M M Bressolle
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.

Authors:  Hiroto Inaba; Jolieke G van Oosterwijk; John C Panetta; Lie Li; Daelynn R Buelow; James S Blachly; Sheila Shurtleff; Ching-Hon Pui; Raul C Ribeiro; Jeffrey E Rubnitz; Stanley Pounds; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2022-06-13       Impact factor: 13.801

6.  Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data.

Authors:  Jon W Collins; J Heyward Hull; Julie B Dumond
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-11-08       Impact factor: 2.745

7.  Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.

Authors:  Ehab S EL Desoky; Eliane Fuseau; Salah EL Din Amry; Valérie Cosson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-12       Impact factor: 2.953

8.  Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.

Authors:  Aksana Vasilyeva; Selvi Durmus; Lie Li; Els Wagenaar; Shuiying Hu; Alice A Gibson; John C Panetta; Sridhar Mani; Alex Sparreboom; Sharyn D Baker; Alfred H Schinkel
Journal:  Cancer Res       Date:  2015-05-07       Impact factor: 12.701

9.  The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments.

Authors:  Tarjinder Sahota; Meindert Danhof; Oscar Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-04-14       Impact factor: 2.745

10.  Use of Mixture Dosing and Nonlinear Mixed Effect Modeling of Eight Environmental Contaminants in Rabbits to Improve Extrapolation Value of Toxicokinetic Data.

Authors:  Véronique Gayrard; Jessika Moreau; Nicole Picard-Hagen; Virginie Helies; Philippe Marchand; Jean-Philippe Antignac; Pierre-Louis Toutain; Roger Leandri
Journal:  Environ Health Perspect       Date:  2021-11-17       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.